Retatrutide vs Ozempic (Semaglutide): Triple Agonist vs Single Agonist Compared

7 min read · Published March 26, 2026 · Reviewed by Dr. [Physician Name]

Ozempic is the GLP-1 medication most Filipinos have heard of. It started the entire weight loss injection conversation. Semaglutide — the molecule behind both Ozempic (for diabetes) and Wegovy (for weight management) — remains the most recognized option in the Philippine market.

Retatrutide is the next evolutionary step: three receptor pathways instead of one, with clinical results that show a substantial performance gap. Here is what the comparison looks like when you move past the brand names and examine the mechanism, data, and practical implications.

Three Receptors vs One

Semaglutide is a single GLP-1 receptor agonist. One metabolic pathway — appetite suppression, slower gastric emptying, improved insulin secretion. Effective. Well-studied. But limited to a single lever.

Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. Everything semaglutide does, plus GIP (enhanced insulin sensitivity, improved fat metabolism) and glucagon (increased resting energy expenditure, accelerated liver fat clearance).

The mechanism gap here is larger than between retatrutide and tirzepatide. Tirzepatide already uses two of the three pathways. Semaglutide uses one.

For the tirzepatide-specific comparison, see retatrutide vs tirzepatide.

The Weight Loss Gap

Semaglutide (STEP-1, 2021): 14.9% average body weight loss at 68 weeks, at the 2.4mg dose, in adults with obesity without diabetes.

Semaglutide in head-to-head (SURMOUNT-5, 2025): 13.7% at 72 weeks — when directly compared to tirzepatide in the same trial.

Retatrutide (Phase 2, NEJM 2023): 24.2% at 48 weeks, at the 12mg dose.

Retatrutide (TRIUMPH-4, December 2025): 28.7% at 68 weeks, at the 12mg dose.

The gap is approximately 14 percentage points. For someone weighing 100kg, that is the difference between losing ~14kg on semaglutide and ~28kg on retatrutide over a similar timeframe.

Cross-trial comparisons carry limitations — different populations, designs, and timepoints. But the magnitude is consistent and likely reflects a genuine pharmacological advantage.

For the detailed breakdown of retatrutide results by dose, see retatrutide weight loss numbers by trial.

Side Effect Comparison

Both share the GLP-1 class gastrointestinal profile. The rates are more similar than you might expect.

Nausea: Retatrutide TRIUMPH-4: ~43%. Semaglutide STEP-1: ~44%. Comparable — suggesting GI tolerability is driven primarily by GLP-1 activation, which both drugs share.

Diarrhea: Retatrutide: ~33%. Semaglutide: ~30%. Similar.

Vomiting: Retatrutide: ~21%. Semaglutide: ~25%. Similar.

The key distinguishing factor is dysesthesia — skin tingling/sensitivity reported in ~21% of retatrutide participants at the highest dose. Not observed with semaglutide. Likely related to the glucagon receptor pathway unique to retatrutide. Generally mild, but a genuinely new consideration.

The other notable difference: some TRIUMPH-4 participants discontinued due to "perceived excessive weight loss." This was not reported in semaglutide trials — consistent with the much larger magnitude of weight loss.

Availability in the Philippines

Semaglutide has the broadest access of any GLP-1 medication in the Philippine market. Branded Ozempic is stocked at many pharmacies. Compounded semaglutide is widely available through telehealth providers at lower price points.

Retatrutide is not available through any legitimate channel. Phase 3 trials are ongoing. Approval is projected for 2027–2028. Products marketed as retatrutide from peptide vendors or social media are unverified.

Tirzepatide sits between them — more effective than semaglutide (20.2% vs 13.7% in head-to-head), available in the Philippines, and the strongest approved option today.

What This Comparison Means Practically

If you are choosing between medications you can access today, the relevant comparison is semaglutide vs tirzepatide. Tirzepatide outperforms semaglutide in head-to-head data and is available through physician-led platforms.

Retatrutide represents the future frontier. The data is compelling. But it does not factor into a treatment decision you can make today.

To understand whether you meet the eligibility criteria for GLP-1 treatment, see who qualifies for retatrutide.

This article is for educational purposes only and does not constitute medical advice. All treatments require evaluation and prescription by a licensed physician. Individual results vary. Kora Health does not guarantee specific outcomes.